HarisAliMD

Hematologic Oncology

Associate Professor/Department of Hematology and Hematopoietic cell transplantation

Dr. Ali is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Division of Leukemia
1500 East Duarte Road
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 626-389-3058

City of Hope National Medical CenterFellowship, Hematopoietic Cell Transplantation, 2012 - 2013
University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
Loma Linda University Health Education ConsortiumResidency, Internal Medicine, 2004 - 2006
MedStar Health/Harbor HospitalInternship, Internal Medicine, 2003 - 2004
Rawalpindi Medical CollegeClass of 2001

PubMed

169 citations
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): A multicenter, open-label phase 2 trial
Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah
Blood. 2020-05-14
2 citations
Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier
Bone Marrow Transplantation. 2023-12-01
2 citations
Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD.
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Hannah Choe
Bone Marrow Transplantation. 2021-11-23

Abstracts/Posters

Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia...
Haris Ali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...
Haris Ali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
Haris Ali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
Haris Ali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

City of Hope Scientists Present Potential New Treatments for Chronic Lymphocytic Leukemia, Myelofibrosis and Other Diseases at American Association of Cancer Research (AACR) Annual MeetingApril 17th, 2023
Adding Itacitinib to Conventional GVHD ProphylaxisDecember 9th, 2022
City of Hope Physicians Report on New CAR-T Cell Therapy for Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm at American Society of Hematology Annual MeetingDecember 11th, 2017
Join now to see all